2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Bleeding and Clotting, Thrombocytopenias, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Aggressive Lymphoma, Research, AML, MDS, MPN, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2539 Combined chronic graft-versus-host-disease‑driven graft-versus-leukemia activity and dasatinib/ponatinib maintenance improve long‑term outcomes after allogeneic hematopoietic stem cell transplantation in advanced Ph+ leukemia

Josephine Lucero, MD, Sihath Singhabahu2, Carol Chen3, Sergio Rodriguez-Rodriguez, MD, MSc4, Eshrak Al-Shaibani, MD5, Tommy Alfaro Moya, MD6, Igor Novitzky-Basso7, Ivan Pasic, BSc8, Fotios Michelis, MD, PhD9, Auro Viswabandya, MBBS MD DM10, Rajat Kumar, FRCPC11, Jonas Mattsson, MD PhD12, Dennis Dong Hwan Kim, MD, PhD13
1 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
2 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
3 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
4 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
5 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, University of Toronto, Toronto, Canada
6 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, University of Toronto, Toronto, Canada
7 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, University of Toronto, Toronto, Canada
8 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, University of Toronto, Toronto, Canada
9 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, University of Toronto, Toronto, Canada
10 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, University of Toronto, Toronto, Canada
11 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, University of Toronto, Toronto, Canada
12 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, University of Toronto, Toronto, Canada
13 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, University of Toronto, Toronto, Canada

Background: Relapse continues to be the leading cause of treatment failure after allogeneic HCT in patients with advanced Ph+ leukemias. Strategies such as leveraging the graft‑versus‑leukemia (GvL) activity linked to chronic GvHD (cGVHD) and using post‑transplant tyrosine kinase inhibitor (TKI) maintenance aim to lower relapse risk, yet the extent of their individual and combined effects—and how these interact with pre‑transplant ABL1 kinase‑domain mutation (KDM) status—remains unclear. Since both cGVHD and TKI maintenance occur only after transplantation, assessing their impact is inherently vulnerable to guarantee‑time bias.

Patients & Methods: We retrospectively studied 135 consecutive patients who underwent allo‑HCT at Princess Margaret Cancer Centre from 2010 to 2025 for BCR::ABL1‑positive leukemia (CML including blast phase n=63; Ph+ ALL n=57; Ph+ AML n=8; MPAL n=7). Median age was 44 years (18–70); donors were unrelated (n=80), matched related (n=40), or haploidentical (n=15). Median follow‑up was 5.6 years. Overall survival (OS) and relapse‑free survival (RFS) were estimated using Kaplan–Meier, and cumulative incidence of relapse (CIR) and non‑relapse mortality (NRM) using competing‑risks methods (Gray’s test). cGVHD and dasatinib/ponatinib maintenance were modeled as time‑dependent covariates (Mantel‑Byar/time‑dependent Cox; cause‑specific for CIR/NRM) with mutual adjustment. Pre‑HCT ABL1 kinase‑domain mutations (positive n=13, T315I n=7) were included as baseline covariates.

Results: Pre‑HCT TKI exposure included imatinib (n=67), dasatinib (n=52), ponatinib (n=35), nilotinib (n=11), bosutinib (n=7), and asciminib (n=3). The predominant sequence was imatinib → dasatinib → ponatinib, with ponatinib reserved for resistant or later‑line disease.

Post‑transplant maintenance (PTM) TKI was initiated at a median of 105 days post‑HCT (IQR 83–128). Thirty‑two patients received dasatinib (n=18), ponatinib (n=16), or both (n=2). Single‑agent TKI was rarely switched. Use of dasatinib/ponatinib (and any TKI) was inversely associated with both any‑grade (p=0.022) and moderate–severe cGVHD (p=0.039). Eight patients developed cGVHD after starting dasatinib/ponatinib; two patients discontinued PTM because of GvHD.

Dasatinib was started at a median of 50 mg/day (range 20–100), maintained at 60 mg/day (20–140), and reached a median maximum of 70 mg/day (20–140). Ponatinib was initiated and maintained largely at 15 mg/day, with occasional escalation to 30–45 mg. Dasatinib was discontinued in 13 of 18 patients (72%) at a median of 11 months, most commonly for toxicity (effusion or pulmonary complications n=3), molecular relapse (n=3), overt relapse (n=2), cytopenia (n=1), or GvHD (n=1). Three patients stopped after completing 2–3 years of PTM without relapse or GVHD. Ponatinib was better tolerated, discontinued in only 4 of 16 patients (25%) for cytopenia, anticipated drug interactions, or GvHD; none discontinued because of relapse.

Two‑year OS, RFS, CIR, and NRM were 64.6%, 57.6%, 17.5%, and 24.9% (median OS 7.5 y; RFS 4.8 y). cGVHD and TKI rarely overlapped (TKI initiated in 15% of cGVHD+ vs 30% of cGVHD− patients), reflecting avoidance of TKI during cGVHD and earlier initiation when cGVHD was absent. In mutually adjusted time‑dependent models, cGVHD independently reduced relapse (HR 0.18, 95% CI 0.05–0.67; p=0.011) without increasing NRM (HR 0.61; p=0.26) and improved RFS (HR 0.40; p=0.010) and OS (HR 0.45; p=0.017). PTM did not reduce relapse (HR 0.50; p=0.24) but was associated with lower NRM (HR 0.10, 0.01–0.75; p=0.025), improving RFS (HR 0.28; p=0.009) and OS (HR 0.21; p=0.009). A composite exposure (cGVHD or TKI, whichever occurred first) was the strongest predictor of survival (OS and RFS HR 0.36, 0.19–0.67; p=0.001). ABL1 KDM had no independent effect on outcomes.

Conclusion: In advanced Ph+ leukemias, cGVHD and post‑transplant dasatinib or ponatinib confer complementary survival benefits—cGVHD providing GvL‑driven relapse control and TKIs reducing non‑relapse mortality—independent of pre‑HCT ABL1 mutation status. These results support a combined immunologic and pharmacologic relapse‑prevention strategy and justify prospective multicenter validation.

Josephine Lucero, MD: No relevant conflicts of interest to declare.